Tenatoprazole
Chemical compound
- none
- 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-imidazo[4,5-b]pyridine
- 113712-98-4 Y
- 636411
- 552196 Y
- RE0689TX2K
- DTXSID1046687
- Interactive image
- Cc1c(OC)c(C)cnc1CS(=O)c2[nH]c3ccc(OC)nc3n2
InChI
- InChI=1S/C16H18N4O3S/c1-9-7-17-12(10(2)14(9)23-4)8-24(21)16-18-11-5-6-13(22-3)19-15(11)20-16/h5-7H,8H2,1-4H3,(H,18,19,20) Y
- Key:ZBFDAUIVDSSISP-UHFFFAOYSA-N Y
Tenatoprazole is a proton pump inhibitor drug candidate that was undergoing clinical testing as a potential treatment for reflux oesophagitis and peptic ulcer as far back as 2003.[1] The compound was invented by Mitsubishi Tanabe Pharma and was licensed to Negma Laboratories (part of Wockhardt as of 2007[2]).[3]: 22
Mitsubishi reported that tenatoprazole was still in Phase I clinical trials in 2007[4]: 27 and again in 2012.[3]: 17
Tenatoprazole has an imidazopyridine ring in place of the benzimidazole moiety found in other proton pump inhibitors, and has a half-life about seven times longer than other PPIs.[5]
See also
References
- ^ "Gastrointestinal Disease Update". Digestive Disease Week. DataMonitor. March 2003.
- ^ "Investors unwilling to forgive Wockhardt, promoter for failings". Economic Times. 3 March 2011.
- ^ a b "State of New Product Development" (PDF). Mitsubishi Tanabe Pharma. 8 May 2012.
- ^ "FY2007 Interim Financial Results". Mitsubishi Tanabe Pharma.
- ^ Li H, Meng L, Liu F, Wei JF, Wang YQ (January 2013). "H+/K+-ATPase inhibitors: a patent review". Expert Opinion on Therapeutic Patents. 23 (1): 99–111. doi:10.1517/13543776.2013.741121. PMID 23205582. S2CID 44647770.
- v
- t
- e
analogues ("-prost-")
("-prazole")
- Azeloprazole
- Dexlansoprazole
- Esomeprazole
- Ilaprazole
- Lansoprazole
- Omeprazole#
- Pantoprazole
- Picoprazole
- Rabeprazole
- Tenatoprazole
- Timoprazole
acid blockers ("-prazan")
- Linaprazan
- Revaprazan
- Soraprazan
- Vonoprazan
- See also: Helicobacter pylori eradication protocols
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III